Secondary cytoreduction in the management of recurrent uterine leiomyosarcoma

Gynecologic Oncology

Volumn 106, Issue 1, 2007, Pages 82-88

  Giuntoli II, Robert L ^a   Garrett Mayer, Elizabeth ^b   Bristow, Robert E ^a   Gostout, Bobbie S ^c  

^a DEPARTMENT OF PATHOLOGY   (United States)

^b JOHNS HOPKINS UNIVERSITY   (United States)

^c MAYO CLINIC   (United States)

Author keywords

Recurrence; Retrospective study; Secondary cytoreductive surgery; Uterine leiomyosarcoma

Indexed keywords

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER LOCALIZATION; CANCER SURGERY; CANCER SURVIVAL; CONTROLLED STUDY; CYTOREDUCTIVE SURGERY; DISEASE FREE INTERVAL; FEMALE; HUMAN; KAPLAN MEIER METHOD; MAJOR CLINICAL STUDY; MEDICAL RECORD REVIEW; MULTIVARIATE ANALYSIS; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; RECURRENT CANCER; RETROSPECTIVE STUDY; SURVIVAL RATE; THERAPY EFFECT; UTERUS MYOMA; UTERUS SARCOMA;

ADULT; AGED; AGED, 80 AND OVER; ANALYSIS OF VARIANCE; CHEMOTHERAPY, ADJUVANT; COHORT STUDIES; FEMALE; HUMANS; LEIOMYOSARCOMA; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; RADIOTHERAPY, ADJUVANT; RETROSPECTIVE STUDIES; SURVIVAL RATE; UTERINE NEOPLASMS;

EID: 34250186054     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2007.02.031     Document Type: Article

References (34)

1. Hannigan E.V., and Gomez L.G. Uterine leiomyosarcoma. Am. J. Obstet. Gynecol. 134 5 (1979) 557-564
2. Major F.J., Blessing J.A., Silverberg S.G., Morrow C.P., Creasman W.T., Currie J.L., et al. Prognostic factors in early-stage uterine sarcoma. A Gynecologic Oncology Group study. Cancer 71 4 Suppl (1993) 1702-1709
3. Mayerhofer K., Obermair A., Windbichler G., Petru E., Kaider A., Hefler L., et al. Leiomyosarcoma of the uterus: a clinicopathologic multicenter study of 71 cases. Gynecol. Oncol. 74 2 (1999) 196-201
4. Peters III W.A., Howard D.R., Andersen W.A., and Figge D.C. Uterine smooth-muscle tumors of uncertain malignant potential. Obstet. Gynecol. 83 6 (1994) 1015-1020
5. Hornback N.B., Omura G., and Major F.J. Observations on the use of adjuvant radiation therapy in patients with stage I and II uterine sarcoma. Int. J. Radiat. Oncol. Biol. Phys. 12 12 (1986) 2127-2130
6. Omura G.A., Major F.J., Blessing J.A., Sedlacek T.V., Thigpen J.T., Creasman W.T., et al. A randomized study of adriamycin with and without dimethyl triazenoimidazole carboxamide in advanced uterine sarcomas. Cancer 52 4 (1983) 626-632
7. Sutton G.P., Blessing J.A., Barrett R.J., and McGehee R. Phase II trial of ifosfamide and mesna in leiomyosarcoma of the uterus: a Gynecologic Oncology Group study. Am. J. Obstet. Gynecol. 166 2 (1992) 556-559
8. Sutton G., Blessing J.A., and Ball H. Phase II trial of paclitaxel in leiomyosarcoma of the uterus: a Gynecologic Oncology Group study. Gynecol. Oncol. 74 3 (1999) 346-349
9. Slayton R.E., Blessing J.A., Angel C., and Berman M. Phase II trial of etoposide in the management of advanced and recurrent leiomyosarcoma of the uterus: a Gynecologic Oncology Group study. Cancer Treat. Rep. 71 12 (1987) 1303-1304
10. Rose P.G., Blessing J.A., Soper J.T., and Barter J.F. Prolonged oral etoposide in recurrent or advanced leiomyosarcoma of the uterus: a Gynecologic Oncology Group study. Gynecol. Oncol. 70 2 (1998) 267-271
11. Anderson S., and Aghajanian C. Temozolomide in uterine leiomyosarcomas. Gynecol. Oncol. 98 1 (2005) 99-103
12. Sutton G., Blessing J.A., and Malfetano J.H. Ifosfamide and doxorubicin in the treatment of advanced leiomyosarcomas of the uterus: a Gynecologic Oncology Group study. Gynecol. Oncol. 62 2 (1996) 226-229
13. Edmonson J.H., Blessing J.A., Cosin J.A., Miller D.S., Cohn D.E., and Rotmensch J. Phase II study of mitomycin, doxorubicin, and cisplatin in the treatment of advanced uterine leiomyosarcoma: a Gynecologic Oncology Group study. Gynecol. Oncol. 85 3 (2002) 507-510
14. Hensley M.L., Maki R., Venkatraman E., Geller G., Lovegren M., Aghajanian C., et al. Gemcitabine and docetaxel in patients with unresectable leiomyosarcoma: results of a phase II trial. J. Clin. Oncol. 20 12 (2002) 2824-2831
15. Abu-Rustum N.R., Curtin J.P., Burt M., and Jones W.B. Regression of uterine low-grade smooth-muscle tumors metastatic to the lung after oophorectomy. Obstet. Gynecol. 89 5 Pt 2 (1997) 850-852
16. Anraku M., Yokoi K., Nakagawa K., Fujisawa T., Nakajima J., Akiyama H., et al. Pulmonary metastases from uterine malignancies: results of surgical resection in 133 patients. J. Thorac. Cardiovasc. Surg. 127 4 (2004) 1107-1112
17. Levenback C., Rubin S.C., McCormack P.M., Hoskins W.J., Atkinson E.N., and Lewis Jr. J.L. Resection of pulmonary metastases from uterine sarcomas. Gynecol. Oncol. 45 2 (1992) 202-205
18. Leitao M.M., Brennan M.F., Hensley M., Sonoda Y., Hummer A., Bhaskaran D., et al. Surgical resection of pulmonary and extrapulmonary recurrences of uterine leiomyosarcoma. Gynecol. Oncol. 87 3 (2002) 287-294
19. Bell S.W., Kempson R.L., and Hendrickson M.R. Problematic uterine smooth muscle neoplasms. A clinicopathologic study of 213 cases. Am. J. Surg. Pathol. 18 6 (1994) 535-558
20. Hendrickson M.R., and Kempson R.L. Pure mesenchymal tumours of the uterine corpus. In: Fox H. (Ed). Haines and Taylor: textbook of obstetrical and gynecological pathology. 4th ed. (1995), Churchill Livingstone, Edinburgh 519
21. International Federation of Gynecology and Obstetrics. Annual report on the results of treatment in gynecologic cancer. Int. J. Gynecol. Obstet. 28 (1989) 189-190
22. Kalbfleisch J.D., and Prentice R.L. The statistical analysis of failure time data (1980), Wiley, New York
23. Liang K.Y., Self S.G., Bandeen-Roche K.J., and Zeger S.L. Some recent developments for regression analysis of multivariate failure time data. Lifetime Data Anal. 1 4 (1995) 403-415
24. Giuntoli II R.L., Metzinger D.S., DiMarco C.S., Cha S.S., Sloan J.A., Keeney G.L., et al. Retrospective review of 208 patients with leiomyosarcoma of the uterus: prognostic indicators, surgical management, and adjuvant therapy. Gynecol. Oncol. 89 3 (2003) 460-469
25. Chi D.S., McCaughty K., Diaz J.P., Huh J., Schwabenbauer S., Hummer A.J., et al. Guidelines and selection criteria for secondary cytoreductive surgery in patients with recurrent, platinum-sensitive epithelial ovarian carcinoma. Cancer 106 9 (2006) 1933-1939
26. Eisenkop S.M., Friedman R.L., and Wang H.J. Secondary cytoreductive surgery for recurrent ovarian cancer. A prospective study. Cancer 76 9 (1995) 1606-1614
27. Gadducci A., Iacconi P., Cosio S., Fanucchi A., Cristofani R., and Riccardo Genazzani A. Complete salvage surgical cytoreduction improves further survival of patients with late recurrent ovarian cancer. Gynecol. Oncol. 79 3 (2000) 344-349
28. Munkarah A., Levenback C., Wolf J.K., Bodurka-Bevers D., Tortolero-Luna G., Morris R.T., et al. Secondary cytoreductive surgery for localized intra-abdominal recurrences in epithelial ovarian cancer. Gynecol. Oncol. 81 2 (2001) 237-241
29. Segna R.A., Dottino P.R., Mandeli J.P., Konsker K., and Cohen C.J. Secondary cytoreduction for ovarian cancer following cisplatin therapy. J. Clin. Oncol. 11 3 (1993) 434-439
30. Tay E.H., Grant P.T., Gebski V., and Hacker N.F. Secondary cytoreductive surgery for recurrent epithelial ovarian cancer. Obstet. Gynecol. 99 6 (2002) 1008-1013
31. Zang R.Y., Zhang Z.Y., Li Z.T., Cai S.M., Tang M.Q., Chen J., et al. Impact of secondary cytoreductive surgery on survival of patients with advanced epithelial ovarian cancer. Eur. J. Surg. Oncol. 26 8 (2000) 798-804
32. Rushing R.S., Shajahan S., Chendil D., Wilder J.L., Pulliam J., Lee E.Y., et al. Uterine sarcomas express KIT protein but lack mutation(s) in exon 11 or 17 of c-KIT. Gynecol. Oncol. 91 1 (2003) 9-14
33. Winter III W.E., Seidman J.D., Krivak T.C., Chauhan S., Carlson J.W., Rose G.S., et al. Clinicopathological analysis of c-kit expression in carcinosarcomas and leiomyosarcomas of the uterine corpus. Gynecol. Oncol. 91 1 (2003) 3-8
34. Klein W.M., and Kurman R.J. Lack of expression of c-kit protein (CD117) in mesenchymal tumors of the uterus and ovary. Int. J. Gynecol. Pathol. 22 2 (2003) 181-184